Merrell Dow's Sabril (vigabatrin or gamma vinyl GABA)
Executive Summary
Merrell Dow's Sabril (vigabatrin or gamma vinyl GABA): Company's request to re-initiate clinical trials with the anticonvulsant drug will be reviewed Nov. 20 by FDA's Peripheral and Central Nervous System Drugs Advisory Committee. Sabril was reviewed by the committee in 1984 and again in 1985 after brain vacuoles were detected in monkeys sacrificed for a toxicity study. The committee recommended that Merrell Dow stop enrolling new human subjects in trials with the drug until it could be demonstrated that any pathological changes were reversible. Patients already on the drug were allowed to continue. Merrell Dow will submit further animal studies and additional human data obtained from foreign trials. Meeting begins at 9 a.m. in Parklawn Conference Rooms D and E.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab With 15 New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.